ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ASMB vs JNJ // GROSS PROFIT MARGIN

Assembly Biosciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ASMB 1 — JNJ 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASMB VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ASMB JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -6.50% 25.50% -32.00 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -9.69% 2.97% -12.66 JNJ /fcf-yield <GO>
Operating Margin -16.80% 34.70% -51.50 JNJ /operating-margins <GO>
Net Profit Margin -8.50% 28.50% -37.00 JNJ /net-margins <GO>
Revenue Growth (YoY) 153.50% 6.00% +147.50 ASMB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.57 5.59 -4.02 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.9 62.1 -26.24 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $424.7M $662.49B -$662.07B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ASMB REV JNJ REV ASMB GROSS % JNJ GROSS % ASMB FCF JNJ FCF
FY 2025 $72.3M $94.19B — 67.9% -$41.2M $19.70B
FY 2024 $28.5M $88.82B — 69.1% -$51.1M $19.84B
FY 2023 $0 $85.16B — — $22.7M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASMB // BETA —
JNJ // BETA 1.08